905 related articles for article (PubMed ID: 10678548)
21. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
22. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
Ke YS; Tao YY; Yang H; Yu GH
Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
[TBL] [Abstract][Full Text] [Related]
23. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
[TBL] [Abstract][Full Text] [Related]
24. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Maschio G; Alberti D; Janin G; Locatelli F; Mann JF; Motolese M; Ponticelli C; Ritz E; Zucchelli P
N Engl J Med; 1996 Apr; 334(15):939-45. PubMed ID: 8596594
[TBL] [Abstract][Full Text] [Related]
25. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F
Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
[TBL] [Abstract][Full Text] [Related]
26. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
Zhang GH; Hou FF; Zhang X; Liu QF
Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):592-6. PubMed ID: 16194413
[TBL] [Abstract][Full Text] [Related]
27. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
29. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
[TBL] [Abstract][Full Text] [Related]
30. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
Pool JL; Glazer R; Weinberger M; Alvarado R; Huang J; Graff A
Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047
[TBL] [Abstract][Full Text] [Related]
31. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
32. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
Bilić M; Munjas-Samarin R; Ljubanović D; Horvatić I; Galesić K
Coll Antropol; 2011 Dec; 35(4):1061-6. PubMed ID: 22397239
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
[TBL] [Abstract][Full Text] [Related]
35. Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients.
Durmus A; Dogan E; Erkoc R; Sayarlioglu H; Topal C; Dilek I
Int J Clin Pract; 2005 Sep; 59(9):1001-4. PubMed ID: 16115171
[TBL] [Abstract][Full Text] [Related]
36. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
Saito I; Saruta T;
Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
[TBL] [Abstract][Full Text] [Related]
37. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
38. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
[TBL] [Abstract][Full Text] [Related]
39. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
[TBL] [Abstract][Full Text] [Related]
40. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
Segura J; Praga M; Campo C; Rodicio JL; Ruilope LM
J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]